JANX — Janux Therapeutics Inc
NASDAQ · Healthcare · Biotechnology
$19.59
+$0.70 (+3.71%)
Janux Therapeutics Inc (JANX) is a biotechnology company listed on NASDAQ. It is led by David Alan Campbell Ph.D., based in 10955 Vista Sorrento Parkway, San Diego, CA, United States, 92130, with about 91 employees. Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms technology to treat patients with cancer. Its clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor that is in Phase 1 clinical trial for the treatment of various solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma, and triple-negative breast cancer. Janux Therapeutics, Inc. has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. The company was incorporated in 2017 and is headquartered in San Diego, California.
Net income was -$24.3M. JANX currently screens at market cap $1.49B.
Use this JANX page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the JANX quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the JANX SEC filings page. Lician reads the product cache first so this HTML stays unique to Janux Therapeutics Inc even when a live quote feed is slow.
About Janux Therapeutics Inc
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms technology to treat patients with cancer. Its clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor that is in Phase 1 clinical trial for the treatment of various solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma, and triple-negative breast cancer. Janux Therapeutics, Inc. has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. The company was incorporated in 2017 and is headquartered in San Diego, California.
JANX Key Statistics
Market Cap
$1.49B
Volume
52,727
Previous Close
$18.60
Day Range
$18.71 – $18.99
EPS
-$1.28
Revenue
$0.00
Net Income
-$68.99M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
91
JANX Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$68.99M | -$58.29M | -$63.06M | -$32.67M |
| EPS (Diluted) | -$1.28 | -$1.32 | -$1.52 | -$1.39 |
Total Assets
$1.06B
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$430.61M
Operating Cash Flow
-$43.81M
Free Cash Flow
$0.00
Janux Therapeutics Inc Company Information
- President, CEO & Director
- David Alan Campbell Ph.D.
- Headquarters
- 10955 Vista Sorrento Parkway, San Diego, CA, United States, 92130
- Website
- www.januxrx.com
- Phone
- 858 751 4493
- IPO / Founded
- 2021-06-11
- Sector
- Healthcare
- Industry
- Biotechnology